215 related articles for article (PubMed ID: 36549759)
1. VEXAS syndrome with progression of MDS to MDS/MPN overlap syndrome.
Neupane K; Jayarangaiah A; Zhang Y; Kumar A
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36549759
[TBL] [Abstract][Full Text] [Related]
2. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1.
Obiorah IE; Patel BA; Groarke EM; Wang W; Trick M; Ombrello AK; Ferrada MA; Wu Z; Gutierrez-Rodrigues F; Lotter J; Wilson L; Hoffmann P; Cardona DO; Patel N; Dulau-Florea A; Kastner DL; Grayson PC; Beck DB; Young NS; Calvo KR
Blood Adv; 2021 Aug; 5(16):3203-3215. PubMed ID: 34427584
[TBL] [Abstract][Full Text] [Related]
3. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.
Georgin-Lavialle S; Terrier B; Guedon AF; Heiblig M; Comont T; Lazaro E; Lacombe V; Terriou L; Ardois S; Bouaziz JD; Mathian A; Le Guenno G; Aouba A; Outh R; Meyer A; Roux-Sauvat M; Ebbo M; Zhao LP; Bigot A; Jamilloux Y; Guillotin V; Flamarion E; Henneton P; Vial G; Jachiet V; Rossignol J; Vinzio S; Weitten T; Vinit J; Deligny C; Humbert S; Samson M; Magy-Bertrand N; Moulinet T; Bourguiba R; Hanslik T; Bachmeyer C; Sebert M; Kostine M; Bienvenu B; Biscay P; Liozon E; Sailler L; Chasset F; Audemard-Verger A; Duroyon E; Sarrabay G; Borlot F; Dieval C; Cluzeau T; Marianetti P; Lobbes H; Boursier G; Gerfaud-Valentin M; Jeannel J; Servettaz A; Audia S; Larue M; Henriot B; Faucher B; Graveleau J; de Sainte Marie B; Galland J; Bouillet L; Arnaud C; Ades L; Carrat F; Hirsch P; Fenaux P; Fain O; Sujobert P; Kosmider O; Mekinian A; ;
Br J Dermatol; 2022 Mar; 186(3):564-574. PubMed ID: 34632574
[TBL] [Abstract][Full Text] [Related]
4. Ocular and orbital manifestations in VEXAS syndrome.
Abumanhal M; Leibovitch I; Zisapel M; Eviatar T; Edel Y; Ben Cnaan R
Eye (Lond); 2024 Jun; 38(9):1748-1754. PubMed ID: 38548942
[TBL] [Abstract][Full Text] [Related]
5. Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome.
Patel N; Dulau-Florea A; Calvo KR
Semin Hematol; 2021 Oct; 58(4):204-211. PubMed ID: 34802541
[TBL] [Abstract][Full Text] [Related]
6. Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome.
Oganesyan A; Hakobyan Y; Terrier B; Georgin-Lavialle S; Mekinian A
Semin Hematol; 2021 Oct; 58(4):247-253. PubMed ID: 34802547
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.
Comont T; Heiblig M; Rivière E; Terriou L; Rossignol J; Bouscary D; Rieu V; Le Guenno G; Mathian A; Aouba A; Vinit J; Dion J; Kosmider O; Terrier B; Georgin-Lavialle S; Fenaux P; Mekinian A;
Br J Haematol; 2022 Feb; 196(4):969-974. PubMed ID: 34651299
[TBL] [Abstract][Full Text] [Related]
8. Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.
Kataoka A; Mizumoto C; Kanda J; Iwasaki M; Sakurada M; Oka T; Fujimoto M; Yamamoto Y; Yamashita K; Nannya Y; Ogawa S; Takaori-Kondo A
Int J Hematol; 2023 Jun; 117(6):919-924. PubMed ID: 36641501
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Coexistence of Multiple Myeloma and Auricular Chondritis in VEXAS Syndrome.
Matsumoto H; Fujita Y; Fukatsu M; Ikezoe T; Yokose K; Asano T; Tsuchida N; Maeda A; Yoshida S; Hashimoto H; Temmoku J; Matsuoka N; Yashiro-Furuya M; Sato S; Murakami M; Sato H; Sakuma C; Kawashima K; Shakespear N; Uchiyama Y; Watanabe H; Kirino Y; Matsumoto N; Migita K
Front Immunol; 2022; 13():897722. PubMed ID: 35757758
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and genetic features of MDS associated with VEXAS syndrome].
Kunimoto H
Rinsho Ketsueki; 2024; 65(4):255-264. PubMed ID: 38684436
[TBL] [Abstract][Full Text] [Related]
11. Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome.
Kunimoto H; Miura A; Maeda A; Tsuchida N; Uchiyama Y; Kunishita Y; Nakajima Y; Takase-Minegishi K; Yoshimi R; Miyazaki T; Hagihara M; Yamazaki E; Kirino Y; Matsumoto N; Nakajima H
Int J Hematol; 2023 Oct; 118(4):494-502. PubMed ID: 37062784
[TBL] [Abstract][Full Text] [Related]
12. VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder.
Huang H; Zhang W; Cai W; Liu J; Wang H; Qin T; Xu Z; Li B; Qu S; Pan L; Huang G; Gale RP; Xiao Z
Exp Hematol Oncol; 2021 Mar; 10(1):23. PubMed ID: 33741056
[TBL] [Abstract][Full Text] [Related]
13. VEXAS syndrome: A dermatological perspective.
Nguyen JK; Routledge D; van Der Weyden C; Blombery P; Angel CM; Johnson D; Goh MS; Lee A
Australas J Dermatol; 2022 Nov; 63(4):488-492. PubMed ID: 36197697
[TBL] [Abstract][Full Text] [Related]
14. VEXAS Syndrome: A Novelty in MDS Landscape.
Templé M; Kosmider O
Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885496
[TBL] [Abstract][Full Text] [Related]
15. VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation.
Cherniawsky H; Friedmann J; Nicolson H; Dehghan N; Stubbins RJ; Foltz LM; Leitch HA; Sreenivasan GM; Ambler KLS; Nevill TJ; McGinnis E; Wilson L; Beck DB; Chen LYC; Marcon KM
Eur J Haematol; 2023 Jun; 110(6):633-638. PubMed ID: 36788756
[TBL] [Abstract][Full Text] [Related]
16. Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review.
Guerrero-Bermúdez CA; Cardona-Cardona AF; Ariza-Parra EJ; Arostegui JI; Mensa-Vilaro A; Yague J; Vásquez G; Muñoz-Vahos CH
Clin Rheumatol; 2022 Nov; 41(11):3565-3572. PubMed ID: 35986821
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease.
Lötscher F; Seitz L; Simeunovic H; Sarbu AC; Porret NA; Feldmeyer L; Borradori L; Bonadies N; Maurer B
Front Immunol; 2021; 12():800149. PubMed ID: 35126364
[TBL] [Abstract][Full Text] [Related]
18. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
19. Case report: diagnosis of VEXAS syndrome in a patient with therapy-resistant large vessel vasculitis.
Boret M; Malfait T
Acta Clin Belg; 2024 Apr; 79(2):143-147. PubMed ID: 38314661
[TBL] [Abstract][Full Text] [Related]
20. VEXAS Syndrome in a Patient with Myeloproliferative Neoplasia.
Austestad J; Madland TM; Sandnes M; Haslerud TM; Benneche A; Reikvam H
Case Rep Hematol; 2023; 2023():6551544. PubMed ID: 36879894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
